Tango Therapeutics and Gilead Sciences to Collaborate on Immuno-Oncology

Posted by ISPE Boston
On November 12, 2018

Cambridge-based Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, has announced a global strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have […]

GO Therapeutics Inks Deal with Roche

Posted by ISPE Boston
On November 1, 2018

Cambridge-based GO Therapeutics, a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, announced in early October that it has entered into a license agreement with Roche. The agreement grants Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target. Under the terms of the agreement, Roche will pay […]

Paratek Wins FDA Approval of “Modernized” Tetracycline

Posted by ISPE Boston
On November 1, 2018

Boston-based Paratek Pharmaceuticals has announced that the FDA has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug […]

Alexion on the Move with Acquisition & Collaboration

Posted by ISPE Boston
On October 30, 2018

Alexion, newly headquartered in Boston’s Seaport District after its move from New Haven, announced in late September that it is acquiring Syntimmune, a clinical-stage biotech developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). Syntimmune’s SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes […]

Stoke Therapeutics Raises $90M to Advance Novel Oligonucleotide Medicines

Posted by ISPE Boston
On October 25, 2018

Bedford-based Stoke Therapeutics has announced it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. Stoke, which launched in 2018 with a $40 million Series A investment, has identified thousands of genes that could be addressed by its proprietary TANGO […]

Takeda Signs $50M Deal with Enterome for Crohn’s Disease Treatment

Posted by ISPE Boston
On October 25, 2018

Enterome, a clinical-stage French biotech with its U.S. headquarters in Cambridge, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. Enterome is developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, […]

Pfizer and Bain Capital Create Cerevel Therapeutics

Posted by ISPE Boston
On October 24, 2018

Bain Capital and Pfizer have announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS) to be headquartered in the greater Boston area. Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical-stage compounds and several […]

Product Show to Attract Thousands on Sept 26th

Posted by ISPE Boston
On September 19, 2018

Join your friends, colleagues, clients and suppliers – and over 350 exhibitors – at the Chapter’s 27th Anniversary Product Show on Wednesday, September 26 at Gillette Stadium. Why attend? Gather Insights – Learn from the industry’s recognized experts during a day-long series of educational programs in four topic areas: Risk Management & Quality, The Future […]

Broad Institute’s CRISPR Patent Affirmed

Posted by ISPE Boston
On September 12, 2018

[The following post has been excerpted from “For Journalists: Statement and Background on the CRISPR Patent Decision” by Lee McGuire, Chief Communications Officer, Broad Institute of MIT and Harvard.] A federal panel has again confirmed that the patents granted by USPTO to the Broad Institute, MIT and Harvard concerning CRISPR editing of eukaryotic genomes do […]

Alnylam Wins EU Approval of Onpattro

Posted by ISPE Boston
On September 12, 2018

Alnylam Pharmaceuticals has announced the European Commission (EC) has granted marketing authorization for Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. The approval was granted less than three weeks after Alnylam won FDA approval for Onpattro. The drug is based on Nobel Prize-winning science […]

Page 1 of 1112 3 ›»